Newsletter | March 6, 2025

03.06.25 -- Clinical Regulatory Changes One of Many Tailwinds for Biosimilars

FEATURED EDITORIAL

Clinical Regulatory Changes One Of Many Tailwinds For Biosimilars

Significant regulatory shifts have reshaped the biosimilar landscape and are projected to reach a value of $35.7 billion in 2025 in the global market. See how biosimilars are slated for considerable growth opportunities, thanks in part to clinical regulatory changes.

Automating Digital Twins Implementation In Downstream Bioprocessing

Developing a downstream process for a new drug candidate is costly due to the high value of the potential drug. Examine a case study in which one researcher simply pressed play on a set of six pre-programmed experiments and returned hours later to a complete data set.

A Look At Pharmaceutical Inspection Machine Advanced Technologies

Pharma and biotech companies are experiencing a rising number of inspection checkpoint mandates, which is leading to an increase in the use of inspection machines with advanced technologies, such as x-ray inspection, robotics, and more, to help them get ahead.

INDUSTRY INSIGHTS

Assessment Of A Biosimilar Interferon In Process Development

Biosimilars are considered to be one of the fastest growing sectors of the pharmaceutical industry. Discover how to develop biosimilars using systems to achieve accurate comparability assessments.

NEWS HEADLINES

Biocon Biologics Launches Yesintek (ustekinumab-kfce) Biosimilar To Stelara In The U.S.

Celltrion Receives EC Approval For Avtozma (CT-P47), A Biosimilar To RoActemra (tocilizumab)

Samsung Bioepis Announces US Launch Of PYZCHIVA (ustekinumab-ttwe), Biosimilar To Stelara

Teva And Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available In The U.S.

Kashiv BioSciences, LLC Obtains Marketing Authorization For Pegfilgrastim Injection From Health Canada

Medimpact Expands Access To Two Biosimilars For Stelara

SOLUTIONS

Innovative Single-Use Tangential Flow Filtration (TFF) Devices